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Abstract
Domestic dogs share the same environment as humans, and they represent a valuable ani-
mal model to study naturally-occurring human disease. Platelet proteomics holds promise
for the discovery of biomarkers that capture the contribution of platelets to the pathophysiol-
ogy of many disease states, however, canine platelet proteomic studies are lacking. Our
study objectives were to establish a protocol for proteomic identification and quantification
of the thrombin-activated canine platelet secretome (CAPS), and to compare the CAPS pro-
teins to human and murine platelet proteomic data. Washed platelets were isolated from
healthy dogs, and stimulated with saline (control) or gamma-thrombin (releasate). Proteins
were separated by SDS-page, trypsin-digested and analyzed by liquid chromatography and
tandem mass spectrometry (MS). CAPS proteins were defined as those with a MS1-abun-
dance ratio of two or more for releasate vs. unstimulated saline control. A total of 1,918 pro-
teins were identified, with 908 proteins common to all dogs and 693 characterized as CAPS
proteins. CAPS proteins were similar to human and murine platelet secretomes and were
highly represented in hemostatic pathways. Differences unique to CAPS included replace-
ment of platelet factor 4 with other cleavage products of platelet basic protein (e.g. interleu-
kin-8), novel proteins (e.g. C-C motif chemokine 14), and proteins in relatively high (e.g.
protease nexin-1) or low (e.g. von Willebrand factor) abundance. This study establishes the
first in-depth platelet releasate proteome from healthy dogs with a reference database of
693 CAPS proteins. Similarities between CAPS and the human secretome confirm the utility
of dogs as translational models of human disease, but we also identify differences unique to
canine platelets. Our findings provide a resource for further investigations into disease-
related CAPS profiles, and for comparative pathway analyses of platelet activation among
species.
Introduction
Comparative studies provide insight into platelet structure, function, and signaling pathways.
For example, species differences in the platelet open canalicular system have been exploited to
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study the kinetics of granule secretion and platelet spreading [1]. Domestic dogs have similar
platelet counts and genetic diversity as human beings, and uniquely among model systems,
companion dogs share the same environment as their owners. The dog is an important large
animal model that has features that complement rodent models used for biomedical research.
Several disease conditions with either primary or secondary platelet involvement, e.g. inherited
platelet defects (such as Glanzmann thrombasthenia [2–4], Scott Syndrome [5, 6], dense gran-
ule storage pool disease [7]), von Willebrand disease [8], disseminated intravascular coagula-
tion [9], immune mediated thrombocytopenia [10], and cancer [11, 12], are shared by dogs
and humans. Dogs with single-gene defects that parallel human hereditary disease have more-
over been used to develop and evaluate the efficacy of novel treatments, including platelet-tar-
geted gene therapy [13]. The application of animal model systems however, has proven more
challenging when studying the role of platelets in complex inflammatory, neoplastic and
degenerative disease syndromes.
In human medicine, platelet proteomics have been used to identify novel proteins and to
characterize changes in proteins in response to activation stimuli or associated with various
disease states [14]. Sample-types for these analyses have included resting platelet lysates [15],
isolated granules [16–19], releasates [20–30], membrane fractions [31, 32] and microparticles
[33–37]. Proteomic analyses of platelets from patients with coronary artery disease have been
used to search for clinically relevant disease biomarkers and novel drug targets [38–41]. A
proteomic approach has also been applied to define the contribution of platelets to the patho-
genesis of sepsis [42], Alzheimer’s disease [43], diabetes mellitus [44], and uremia [45]. Com-
mon to these clinical studies are the altered platelet protein profiles and the emerging evidence
that platelet-derived proteins might provide disease-specific biomarker fingerprints. With the
exception of a single study of hereditary canine Scott syndrome, in which proteomics con-
firmed a mutation of a platelet membrane protein as the causative platelet defect [46], no plate-
let proteomic investigations have been undertaken in dogs.
To extend the utility of dogs as a model system for inherited and acquired disease, and to
provide a healthy CAPS reference profile for future disease-related canine studies, the present
study aimed to establish a protocol for the identification and quantification of proteins
secreted from activated canine platelets. The protein signature of the gamma-thrombin
induced canine platelet secretome (CAPS) was established in healthy dogs using shotgun pro-
teomics. We compared all identified canine platelet proteins with a previously described global
human platelet proteome [15], and compared CAPS proteins with human [29] and murine
[47] platelet secretomes. As shotgun proteomic profiling has never been reported in dogs
before, the established protocol was based on the human literature, with necessary adjustments
implemented to accommodate for species differences, as detailed below.
Materials and methods
Blood sampling and platelet isolation
The work flow is depicted in Fig 1. Acid citrate dextrose (ACD-A) anticoagulated whole blood
samples (18 mL) were obtained from the cephalic vein of three healthy dogs as previously
detailed [5]. One dog was a client-owned 5-year-old mixed breed spayed female and the other
two dogs were a 6-year-old castrated male hound and a 3-year-old intact male beagle housed
at an American Association for Accreditation of Laboratory Animal Care-approved facility.
All procedures for animal use were reviewed and approved by the Institutional Animal Care
and Use Committee at Cornell University (IACUC protocol no. 1994–0089), and owner con-
sent was obtained. To account for the smaller body size and blood volume of dogs, the sample
volume collected was less than used in human studies [24, 25, 29]. In order to maximize the
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Fig 1. Experimental design flow chart. Platelets were isolated and washed free of plasma by serial centrifugation, divided into two
aliquots and activated with saline (control) or gamma-thrombin. The releasate was cleared of debris and then fractionated by ultra-
centrifugation into particulate (pellet) and soluble fractions. Proteins were separated by SDS-page, trypsin digested and analyzed by
nanoLC-MS/MS.
https://doi.org/10.1371/journal.pone.0224891.g001
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platelet yield from canine whole blood, the samples were diluted to a final volume of 50 mL
with wash buffer (113 mM NaCl, 4.3 mM K2HPO4, 4.2 mM Na2HPO4, 24.4 mM NaH2PO4,
5.5 mM glucose, pH 6.3) plus 1.25 μM PGE1 (P7527, Sigma Aldrich) and 0.04 U/mL apyrase
(Sigma type VII, A6535, 200 U/mg protein). The samples were gently mixed and then centri-
fuged in a swing-out rotor (Sorvall Legend XTR Centrifuge, ThermoFisher Scientific US) at
650 x g for 5 min at room temperature (RT) without braking (remaining centrifugations were
performed with brake). Thirty milliliters of the resultant dilute platelet rich plasma (dPRP)
supernatant was collected, and to further maximize the platelet yield, the remaining 20 mL
resuspended in 30 mL wash buffer plus 0.04 U/mL apyrase. The resuspended cells were centri-
fuged at 650 x g for 5 min at RT. Platelets in the upper 30 mL of this second supernatant were
removed and combined with the first 30 mL dPRP, with the addition of wash buffer with 0.04
U/mL apyrase to a final volume of 100 mL. The dPRP (60 mL total) was mixed, and a 500 μL
aliquot was removed for a complete blood cell count (CBC) (Advia2120 Hematology System,
Siemens, USA). Equal volumes of dPRP were divided between two 50 mL polypropylene
tubes and spun at 1,250 x g for 1 min at RT, to remove contaminating RBCs and WBCs. The
supernatant was divided equally between four 50 mL polypropylene tubes, and the platelets
sedimented at 1,250 x g for 10 min at RT to achieve efficient washed platelet recovery. The
supernatant was discarded, and the inside of the tube wiped dry to further remove plasma pro-
teins. The platelets were subjected to a final wash step by resuspending the four platelet pellets
in 80 mL of wash buffer containing 0.02 U/mL apyrase. Each wash step was followed by collec-
tion of a 500 μL aliquot for a CBC. The platelets were pelleted by centrifugation at 1,250 x g for
10 min at RT. The supernatant was removed, the inside of the tubes wiped dry once more for
removal of contaminants, and the washed platelets resuspended in 2.1 mL activation buffer
(137 mM NaCl, 4 mM KCl, 0.5 mM MgCl-6H2O, 0.5 mM Na2HPO4, 0.1% glucose, 30 mM
HEPES, pH 7.4). An aliquot of 25 μL was removed into 475 μL wash buffer for a CBC. The
number of recovered washed platelets was 1.1 x 109/mL, 5.8 x 108/mL and 4.0 x 108/mL,
respectively, corresponding to concentrations reported in human studies [20, 26, 30, 48–50].
Washed platelet concentration was not adjusted to a standardized number because platelet
yield varied; dilution would have resulted in washed PRP concentrations below acceptable lim-
its for activation. Prior to activation, the platelets were rested for 10 minutes at 37˚C followed
by 20 minutes at RT for platelet cAMP levels to return to basal levels.
Baseline ex-vivo platelet activation
Flow cytometry was utilized to detect ex-vivo platelet activation due to washing, evaluate the
response of washed platelets to agonist stimulation, and to detect residual leukocytes in the
platelet suspensions. Two microliters of post-washing samples were diluted in 1 mL PBS con-
taining 0.4 mM gly-pro-arg-pro-NH2 acetate (Sigma Aldrich, USA) and stimulated with
human gamma-thrombin (Haematologic Technologies Inc., USA) at 50 nM final concentra-
tion for 10 min at 37˚C without stirring. Platelets were labelled with mouse monoclonal anti-
human CD9-FITC (clone H19a, Biolegend, San Diego, CA, USA, Antibody Registry Identifier:
AB_314908) [51] in a 1:1000 final dilution and either mouse monoclonal anti-human
CD62P-PE (clone AC1.2, BD Biosciences, San Diego, CA, USA, Antibody Registry Identifier:
AB_2184974) [52] in a 1:10 final dilution to detect P-selectin expression or rat monoclonal
anti-human CD18-PE (Clone YFC118.3, AbD Serotec, Oxford, England, Antibody Registry
Identifier: AB_321328) in a 1:20 final dilution to identify leukocytes [51]. An isotype antibody
conjugated with PE (BD, Biosciences) was used to define nonspecific antibody binding. Cell
suspensions were incubated in the dark for 20 min at RT, quenched with 500 μL PBS and ana-
lyzed within 30 min on a flow cytometer (FacsCalibur, BD Biosciences, USA). Platelet
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populations were defined based on forward scatter (FCS), side scatter (SSC) and CD9 fluores-
cence. Degranulation, based on CD62P-PE fluorescence within the platelet gate, was deter-
mined with and without thrombin activation (S1 Fig). Leukocyte contamination was detected
based on the presence of CD18 positive events counted within predefined leukocyte gates (S2
Fig).
Gamma-thrombin activation and releasate collection
Platelet aggregation was monitored using a PAP-8E light-transmission aggregometer (Bio/
Data Corporation, USA). Briefly, 450 μL of rested, washed platelets suspension and 4.5 μL 200
mM CaCl2 were added to 4 individual cuvettes and stirred at 1,000 RPM for 2 min at 37˚C
prior to addition of 50 μL vehicle control (0.15 M NaCl) or gamma-thrombin (50 nM final
concentration). The reaction proceeded with continuous recording for control and gamma-
thrombin stimulated samples, respectively, at 37˚C with stirring for 6 min. The sample was
then placed on ice, followed by addition of EDTA (5 mM final concentration) and 2x protease
inhibitor cocktail (HaltTM Protease and Phosphatase Inhibitor, Thermo Scientific, USA) before
transfer to 1.5 mL Eppendorf tubes. Platelets and aggregates were removed by serial two-step
centrifugation at 1,000 x g for 10 min at 4˚C, isolating the platelet releasate. Approximately
950 μL releasate was recovered and stored at -80˚C. A 60 μL aliquot was reserved for protein
analysis (PierceTM BCA Protein Assay Kit, Thermo Scientific, USA).
Fractionation and concentration of releasate
Control and thrombin-activated releasate samples were thawed at 37˚C, transferred to individ-
ual, 3.5 mL, polycarbonate tubes (Beckman Coulter, USA) and centrifuged at 50,000 x g for 1
hour at 5˚C (OptimaTM L-90K Ultracentrifuge, Beckman Coulter, USA). The supernatants
(soluble fraction) and pellets (particulate fraction including microparticles) were separated
and the pellets were stored at -80˚C. Soluble fractions were concentrated by centrifugal filtra-
tion using a 0.5 mL, 15 kDa cut-off filtration device (Merck Millipore, Ireland). A 10 μL aliquot
was removed and diluted with 50 μL activation buffer for protein analysis. The remaining con-
centrate and the flow-through samples were stored at -80˚C.
SDS-page and in gel tryptic digestion
The four samples generated for each dog (thrombin-stimulated and saline control samples for
the soluble and the pellet fractions, respectively) were separated by SDS-page on 12% TGX pre-
cast gels (Bio Rad, USA). For the thrombin-stimulated samples, 5 μg was loaded pr. lane, and
the equivalent sample volume was loaded for the respective control samples. The gels were
fixed in 50% methanol, 43% water, and 7% acetic acid, and then rehydrated prior to colloidal
Coomassie blue staining, as previously described (Fig 2) [46]. For each lane of the SDS-PAGE
gel, four gel slices equivalent for each dog, were cut based on band intensity into 1 mm cubes
and subjected to in-gel digestion followed by extraction of the tryptic peptides as reported pre-
viously [53]. The excised gel pieces were washed consecutively in 200 μL distilled water, 100
mM ammonium bicarbonate (Ambic)/ACN (1:1) and ACN. The gel pieces were reduced with
70 μL of 10 mM DTT in 100 mM Ambic for 1 hr at 56˚C, alkylated with 100 μL of 55 mM
iodoacetamide in 100 mM Ambic at RT in the dark for 60 minutes. After wash steps as
described above, the gel slices were dried and rehydrated with 50 μL trypsin in 50 mM Ambic,
10% ACN (20 ng/μL) at 37˚C for 16 hrs. The digested peptides were extracted twice with 70 μL
of 50% ACN, 5% formic acid (FA) and once with 70 μL of 90% ACN, 5% FA. Extracts from
each sample were combined and lyophilized.
Platelet proteomics in dogs
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In solution digestion of flow-through samples
Flow-through fractions containing proteins not retained by the filtration device were collected
for control and stimulated dog samples. Prior to in-solution proteomic analyses they were
pooled for each experimental group. Sample preparation of S-Trap micro spin column (Pro-
tiFi, Huntington, NY, USA) was according to the vendor’s protocol and Zougman et al. [54,
55]. Four hundred microliter were taken from each sample. This corresponded to 9.6 μg pro-
tein from the stimulated sample and 1.1 μg protein from the control sample, which, respec-
tively, were mixed with 50 mM iodoacetamide (final concentration) for 45 min in the dark at
room temperature. 12% aqueous phosphoric acid was added at 1:10 for a final concentration
of 1.2%, and S-Trap buffer (90% methanol in 100 mM triethylammonium bicarbonate
(TEAB), pH7.1) was added to form colloidal protein particulate. Protein mixtures were trans-
ferred into the S-Trap micro column and centrifuged at 4,000 x g for 10 min, and washed with
150 μL S-Trap buffer. Finally, 12 μL trypsin buffer (0.5 μg trypsin in 50 mM TEAB) was added
and digested at 37˚C for 16–18 h. For peptide elution collection, 40 μL TEAB was added into
micro spin column and centrifuged at 4,000 x g for 10 min and washed twice with 50 μL 50%
ACN containing 0.2% FA solution. The digested peptides were dried in Speed Vacuum.
Nano liquid chromatography and mass spectrometry
Lyophilized tryptic peptides extracted from the gel were reconstituted in a total volume of
73 μL of 0.5% FA for each dog. Reconstitution volumes were varied (10–20 μL) for lyophilized
tryptic peptides from gel segments based on their protein content. Peptides were analyzed by
nano-LC-ESI MS/MS in single technical replicates [56] using an Orbitrap FusionTM TribridTM
(Thermo-Fisher Scientific, San Jose, CA) mass spectrometer equipped with a nanospray Flex
Ion Source, and coupled with a Dionex UltiMate 3000 RSLCnano system (Thermo, Sunnyvale,
Fig 2. Excision strategy for in-gel digestion. Regions excised for in-gel digestion are shown for two dogs. Soluble
fraction control samples (lanes 1 and 5, respectively), soluble fraction thrombin-stimulated samples (lanes 2 and 6,
respectively), pellet fraction control samples (lanes 3 and 7, respectively) and pellet fraction thrombin-stimulated
samples (lanes 4 and 8, respectively). The red bars indicate the excised regions used to generate tryptic digests for
nano-LC and MS/MS. Molecular weight markers are shown.
https://doi.org/10.1371/journal.pone.0224891.g002
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CA) [54, 57]. Reconstituted peptides from individual gel segments and in-solution digests
were injected (10–20 μL) onto a PepMap C-18 RP nano trapping column (5 μm, 100 μm i.d. x
20 mm) at 20 μL/min flow rate for rapid sample loading and then separated on a PepMap C-
18 RP nano column (2 μm, 75 μm x 25 cm) at 35˚C. Column peptide load was monitored by
MS signal intensity. The tryptic peptides were eluted in a 120 min gradient of 5% to 38% ACN
in 0.1% FA at 300 nL/min, followed by a 7 min ramping to 90% ACN-0.1% FA and an 8 min
hold at 90% ACN-0.1% FA. The column was re-equilibrated with 0.1% FA for 25 min prior to
the next run. The Orbitrap Fusion was operated in positive ion mode with spray voltage set at
1.6 kV and source temperature at 275˚C. External calibration for FT, IT and quadrupole mass
analyzers was performed. For in data-dependent acquisition (DDA) analysis, the instrument
was operated using FT mass analyzer in MS scan to select precursor ions followed by 3 second
“Top Speed” data-dependent collision-induced dissociation ion trap MS/MS scans at 1.6 m/z
quadrupole isolation for precursor peptides with multiple charged ions above a threshold ion
count of 10,000 and normalized collision energy of 30%. MS survey scanned at a resolving
power of 120,000 (FWHM at m/z 200), for the mass range of m/z 375–1575. Dynamic exclu-
sion parameters were set at 40 s of exclusion duration with ±10 ppm exclusion mass width. All
data were acquired under Xcalibur 3.0 operation software (Thermo-Fisher Scientific). It
should be noted that the nanoLC column used for dog 1 differed from dogs 2 and 3, as dog 1
was analyzed prior to the two other dogs. Stored samples from dog 1 however, were re-ana-
lyzed at the same time as dog 2 and 3.
Protein identification and quantification
The DDA raw files for CID MS/MS were subjected to database searches using Proteome Dis-
coverer 2.2 (PD 2.2) software (Thermo Fisher Scientific, Bremen, Germany) with the Sequest
HT algorithm. All four raw MS files of the four gel slices for each soluble and pellet sample
(stimulated vs saline control, respectively) were combined for searching against a Canis lupus
familiaris RefSeq database (CanFam3.1, downloaded from NCBI on Jan. 12, 2018) containing
45,326 entries plus a common contaminant database of 246 entries [58]. Two-missed trypsin
cleavage sites were allowed. Peptide precursor tolerance was set to 10 ppm and fragment ion
tolerance was set to 0.6 Da. Variable modification of methionine oxidation, deamidation of
asparagine/glutamine and fixed modification of cysteine carbamidomethylation were set for
the database search. High confidence peptides defined by Sequest HT with a 1% false discovery
rate by Percolator were considered for identification. Relative quantitation of identified pro-
teins between thrombin-stimulated and saline control samples, for pellet and soluble fractions,
was determined by the Label Free Quantitation workflow in PD 2.2. Precursor abundance
intensity for each peptide identified, was automatically determined and unique peptides for
each protein were summed and used to calculate the protein abundance (the MS1-abundance)
within the PD 2.2 software without normalization. Protein ratios were calculated based on
pairwise ratios for stimulated/saline control samples. All protein raw data output files can be
found in the supportive information.
Bioinformatic analysis
Proteins identified in the flow-through samples were combined with those identified in the
soluble fractions. Protein lists were curated to remove duplicates and dog RefSeq accession
numbers were converted to the homologous human Entrez Gene IDs using bioDBnet (https://
biodbnet-abcc.ncifcrf.gov). The proteins were then compared to the reported human global
platelet proteome [15], the recently reported core human [29] and murine thrombin releasates
[47]. For this, human protein identifiers were mapped to Entrez Gene IDs using the MyGene
Platelet proteomics in dogs
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module in Python (http://www.ebi.ac.uk/Tools/picr/). Canine proteins not matched, were
manually reviewed. Proteins were considered a match to a human protein counterpart when
identified as a precursor protein, annotated with the qualifier “like protein” or present in a sin-
gle protein isoform. Redundant protein species were considered splice variants.
Proteins present in a minimum of 2/3 dogs having an MS-1 abundance ratio for paired
stimulated/control samples greater than or equal to two [30] were defined as CAPS proteins.
This avoided skewing the data set in favor of releasate proteins represented at highest abun-
dance. The CAPS proteins were subjected to Gene Ontology (GO) analysis, and all dog RefSeq
gene accession numbers and their GO terms were collected with R Bioconductor (https://
bioconductor.org), using R Bioconductor package biomaRt [59]. This set was used for the
gene enrichment analysis for gene ontology with R Bioconductor package topGO. Signal path-
way enrichment analysis on the Reactome database [60] was performed with Enrichr web
server [61]. Lastly, the abundance ranking of the CAPS proteins were manually compared to
that of the human [29] and murine [47] secretomes.
Results
Sample purity
For all dogs, there was minimal contamination from other cells. No RBC or WBC were
detected in CBCs of the final platelet suspensions, and flow cytometry demonstrated <0.1% of
CD18-expressing cells (leukocytes). Major RBC proteins, glycophorin A, band 3 anion trans-
porter (both approximately 106 copies /RBC [62]) and hemoglobin (109 copies /RBC [15])
were identified in concentrations indicating a maximum of 1–2 RBC/mL of final platelet sus-
pension (S1 Table). The specific neutrophil protein, CD177 (2.5–7.5 x 104 copies/cell [63]) was
found with a maximal MS1 abundance of 1.2 x 105, corresponding to 2–5 neutrophils/mL. The
lymphocyte protein, CD83, was present in a single dog in trace amounts.
Platelet activation status
Post-washing platelet activation status, based on CD62P expression, was low [22] for the three
dogs, at 0.7%, 5.9% and 8.1%, respectively. When subjected to gamma-thrombin activation,
platelet CD62P expression was 65.1%, 70.6% and 77.9%, respectively. Platelets from all three
dogs demonstrated robust aggregation response to thrombin and undetectable aggregation in
stirred saline controls (S3 Fig).
Platelet protein identification
A total of 1,918 platelet proteins were identified from three biological replicates (S1 Table).
Individually, 1,090, 1,467 and 1647 proteins were identified from dogs 1, 2 and 3, respectively,
and 908 proteins were identified in all three dogs. Of the 1,918 total proteins, 647 were found
in the soluble fraction, 447 in the pellet fraction and 824 proteins were found in both fractions.
Two or more peptides were used to confidently identify 70.1% of the canine platelet proteins,
while 29.9% were identified using a single unique peptide.
Of the total canine proteins, 1,593 (83.1%) were also found in the global human platelet
proteome of 4,116 proteins reported by Burkhart et al. 2012 [15] (S2 Table). Fig 3 shows the
number of proteins overlapping between the two datasets, and the fraction (soluble or pellet)
in which they were identified. A total of 325 canine proteins were not included in the human
global platelet proteome, and of those, 66 (20.3%) were detected in all three dogs. These pro-
teins were searched in PubMed for association with human platelets, megakaryocytes, throm-
bocytes, alpha-granules and dense granules, and they were searched in a human MS1
Platelet proteomics in dogs
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proteome database for cell type and tissue expression. Proteins previously associated with
platelets or other vascular compartment cells were removed, leaving 3 proteins; C-C motif che-
mokine 14, teneurin-3 and protein-arginine deiminase type-3, that may represent novel plate-
let secretion proteins.
The canine platelet secretome (CAPS)
A total of 693 CAPS proteins were identified (S3 Table), comprising 360 proteins present only
in the soluble fraction, 189 only in the pellet fraction, and 144 in both fractions. Fifty CAPS
proteins (7.2%) were low abundance, identified from a single unique peptide.
To verify the quality and platelet relevance of the CAPS profile, enrichment analyses of GO-
annotations and cell-signal pathways were performed. For biological process, 12 of the top 20
Fig 3. Venn diagram analysis. Comparison of all identified canine platelet proteins to the global platelet lysate
proteome reported by Burkhart et al. 2012. The diagram shows the number of human lysate proteins shared with the
canine secretome (1593), the number of lysate proteins that were not co-identified (2693), and the number of canine
proteins that were not reported in the human platelet lysate (325). For the canine proteins, the figure also illustrates the
number of proteins in the soluble fraction (647), pellet fraction (447) or both fractions (824).
https://doi.org/10.1371/journal.pone.0224891.g003
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most significantly enriched annotations were directly related to hemostasis, with the top five
containing ‘coagulation’, blood coagulation’, ‘hemostasis’, and ‘wound healing’ (Table 1). Sig-
nificantly enriched GO-annotations for cellular compartment included ‘secretory vesicle’,
‘platelet alpha-granule’, ‘fibrinogen complex’ and ‘secretory granule’ (S4 Table), and molecular
function was dominated by ‘binding’ and ‘enzyme regulator activity’ (S5 Table).
Fig 4 shows the association of the CAPS proteins with the 30 most enriched signal path-
ways. The top 20 proteins of the clustergram were enriched in all of the 30 listed pathways
except for the top four pathways; ‘platelet activation, signaling and aggregation’, ‘hemostasis’,
‘response to elevated platelet cytosolic Ca++’, and ‘platelet degranulation’. These four pathways
had a more distinct and highly similar protein fingerprint.
The table lists the 20 most significantly enriched GO-annotations for the 693 CAPS proteins
found in at least 2/3 dogs with a stimulated/control ratio equal or above two.
Analysis link: http://amp.pharm.mssm.edu/Enrichr/enrich?dataset=72rsm
The 693 CAPS proteins were compared to the 276 core human proteins and the top 100
murine proteins identified in the releasate of thrombin-activated platelets reported by Parsons
et al. 2018 [29] and Martı´n-Granado et al. 2017 [47], respectively (S3 Table). Of the human
core, 160 proteins (58%) were co-identified, and another 62 (22.5%) were detected in the sub-
set of canine proteins that had MS1 sample/control ratios less than two (S1 Table). Fifty-four
of the human core proteins (19.5%) were not identified in the canine platelet fractions we ana-
lyzed (Table 2). Of the murine secretome proteins, 78% were found in the dogs (S1 Table) and
50% were found among the CAPS proteins (S3 Table).
The table lists the 54 proteins found in the human core secretome [29] that were not present
in the canine dataset.
Quantitative comparisons between the most abundant CAPS and human [29] and murine
[47] platelet secretomes are displayed in Table 3 (top 30) and in S6 Table (top 100). Differences
included relative deficiencies of canine vWF and coagulation factor V, ranked 288 and 298,
Table 1. Significantly enriched GO-annotations for ‘biological process’.
GO ID GO Term Annotated CAPS proteins P
GO:0050817 Coagulation 30 2.7e-18
GO:0007596 Blood coagulation 29 3.2e-18
GO:0007599 Hemostasis 29 5.7e-18
GO:0052547 Regulation of peptidase activity 43 8.1e-18
GO:0042060 Wound healing 39 3.5e-17
GO:0010951 Negative regulation of endopeptidase activity 32 1.4e-16
GO:0006508 Proteolysis 100 1.6e-16
GO:0052548 Regulation of endopeptidase activity 40 2.4e-16
GO:0010466 Negative regulation of peptidase activity 32 3.9e-16
GO:0009611 Response to wounding 41 6.6e-16
GO:0045861 Negative regulation of proteolysis 36 3.7e-15
GO:0072376 Protein activation cascade 15 9.7e-15
GO:0072378 Blood coagulation, fibrin clot formation 9 4.8e-14
GO:1901564 Organonitrogen compound metabolic process 250 7.5e-14
GO:0030193 Regulation of blood coagulation 18 1.1e-13
GO:1900046 Regulation of hemostasis 18 1.1e-13
GO:0050818 Regulation of coagulation 19 1.4e-13
GO:0030162 Regulation of proteolysis 52 6.3e-13
GO:0042730 Fibrinolysis 11 7.5e-13
GO:0061041 Regulation of wound healing 20 1.7e-11
https://doi.org/10.1371/journal.pone.0224891.t001
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respectively (S3 Table), and alpha-2-macroglobulin that did not meet the criteria for a CAPS
protein. Among the highly abundant canine releasate proteins (top 20–30), fibronectin, metal-
loproteinase inhibitor 1 and Trem-like protein 1 were absent in the top 100 of either the
human or the murine secretome. Other abundant canine proteins, including the C-C motif
chemokine 14 and the potent serine protease inhibitor, protease nexin-1 (PN-1) were absent
from the top 100 secreted proteins for both humans and mice.
In the table, the top 30 most abundantly secreted platelet proteins in dogs are compared
with those of humans [29] and mice [47]. Noteworthy differences are highlighted in bold.
Discussion
The present study is the first proteomic profiling to define a canine secretome, or CAPS, repre-
senting platelet response to thrombin stimulation. The reactome derived from GO annotation
confirms the role of the CAPS proteins in platelet activation and demonstrates conservation
across species in platelet participation in the immune response and platelet metabolism. The
observed clustering of CAPS proteins within functional pathways provides a resource to
Fig 4. Signal pathway enrichment analysis. A: Clustergram illustrating the relationship between CAPS proteins (rows) and the 30 most enriched pathways
(columns) for the 693 CAPS proteins. Proteins are ranked within a pathway from high to low frequency, and the pathways� are ranked according to the
significance-level of enrichment (decreasing enrichment-level left to right). Proteins rarely enriched and unique to individual pathways cluster near the bottom.
B: Highlight of the 60 most frequently enriched proteins of the clustergram. Approximately 20 proteins are enriched in the majority of the pathways, but not in
the most significantly enriched (pathways 1–4), which share a similar and distinct protein fingerprint. �) Pathways: 1. Platelet activation, signaling and
aggregation. 2. Hemostasis. 3. Response to elevated platelet cytosolic Ca++. 4. Platelet degranulation. 5. Innate immune system. 6. Immune system. 7. Signaling
by VEGF. 8. VEGFA-VEGFR2 pathway. 9. Metabolism. 10. Axon guidance. 11. Interleukin-3, 5 and GM-CSF signaling. 12. Signaling to ERKs. 13. NGF-
signaling via TRKA from the plasma membrane. 14. Signaling by PDGF. 15. IGF1R signaling cascade. 16. IRS-related events triggered by IGF1R. 17. Signaling
by Type 1 IGF1R. 18. DAP12 signaling. 19. Signaling to RAS. 20. G2/M transition.21. Adaptive Immune System. 22. Mitotic G2-G2/M phases. 23. IRS-
mediated signaling. 24. Signaling by NGF. 25. Signaling by NGF receptor. 26. Insulin-receptor signaling cascade. 27. Downstream signal transduction. 28. C-
type lectin receptors (CLRs). 29. Prolonged ERK activation events. 30. Host interactions of HIV factors.
https://doi.org/10.1371/journal.pone.0224891.g004
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Table 2. Human secretome proteins not found in dogs.
Gene name Protein name
ACTB Actin, cytoplasmic 1
APLP2 Amyloid-like protein 2
APOA2 Apolipoprotein A-II
APOA4 Apolipoprotein A-IV
APOB Apolipoprotein B-100
APOC1 Apolipoprotein C-I
C9 Complement component C9
CCL5 C-C motif chemokine 5
CD36 Platelet glycoprotein 4
CFHR1 Complement factor H-related protein 1
CTGF Connective tissue growth factor
CTSW Cathepsin W
CXCL3 C-X-C motif chemokine 3
DAG1 Dystroglycan
FSTL1 Follistatin-related protein 1
GP5 Platelet glycoprotein V
HSPA1B Heat shock 70 kDa protein 1B
IGHA1 Ig alpha-1 chain C region
IGHG2 Ig gamma-2 chain C region
IGHG3 Ig gamma-3 chain C region
IGHG4 Ig gamma-4 chain C region
IGHM Ig mu chain C region
IGHV3-23 Ig heavy chain V-III region TIL
IGHV3-33 Ig heavy chain V-III region KOL
IGHV3-72 Immunoglobulin heavy variable 3–72
IGKC Ig kappa chain C region
IGKV1-5 Ig kappa chain V-I region EU
IGKV2D-28 Ig kappa chain V-II region TEW
IGKV3-20 Ig kappa chain V-III region WOL
IGKV4-1 Ig kappa chain V-IV region Len
IGLC2 Ig lambda-2 chain C regions
ITIH3 Inter-alpha-trypsin inhibitor heavy chain H3
LGALS3BP Galectin-3-binding protein
MMP1 Interstitial collagenase
N/A Uncharacterized protein
NRGN Neurogranin
NUCB1 Nucleobindin-1
ORM1 Alpha-1-acid glycoprotein 1
ORM2 Alpha-1-acid glycoprotein 2
PCSK6 Proprotein convertase subtilisin/kexin type 6
PDGFD Platelet-derived growth factor D
PF4 Platelet factor 4
PF4V1 Platelet factor 4 variant
QSOX1 Sulfhydryl oxidase 1
RAB27B Ras-related protein Rab-27B
RNASET2 Ribonuclease T2
S100A4 Protein S100-A4
(Continued)
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explore the contribution of individual platelet proteins in the complex processes of hemostasis,
immune response, and tissue repair.
We obtained a highly pure platelet suspension, and documented platelet activation status,
including aggregability, in washed, unstimulated control samples and after thrombin stimula-
tion. In the characterization of CAPS proteins, we considered the background signal from
Table 2. (Continued)
Gene name Protein name
SDC4 Syndecan-4
SDPR Serum deprivation-response protein
SERPING1 Plasma protease C1 inhibitor
SPARC SPARC
ST3GAL6 Type 2 lactosamine alpha-2,3-sialyltransferase
TGFBI Transforming growth factor-beta-induced protein ig-h3
VEGFC Vascular endothelial growth factor C
https://doi.org/10.1371/journal.pone.0224891.t002
Table 3. Inter-species platelet secretome comparisons.
Canine top 30 Human top 30 Murine top 30
Thrombospondin-1 Serum albumin Serum albumin
Fibrinogen alpha chain Thrombospondin-1 Thrombospondin 1
Fibrinogen beta chain Platelet basic protein Serotransferrin
Fibrinogen gamma chain isoform X1 Talin-1 Platelet factor 4
Fibronectin isoform X7 Complement C3 Alpha-2-macroglobulin
Serum albumin precursor Filamin-A Actin, cytoplasmic 1
Gelsolin Serotransferrin Talin-1
Platelet basic protein precursor Myosin-9 Actin, cytoplasmic 2
C-C motif chemokine 14 Actin, cytoplasmic 2 Apolipoprotein A-I
Profilin-1 von Willebrand factor Hemoglobin subunit alpha
Metalloproteinase inhibitor 1 isoform X1 Multimerin-1 Fibrinogen alpha chain
Tubulin beta-4B chain isoform X2 Alpha-2-macroglobulin Hemoglobin subunit beta-1
Cofilin-1 Platelet factor 4 variant Ig mu chain C region (Fragment)
Tubulin alpha-4A chain isoform X1 Uncharacterized protein Hemopexin
Peptidyl-prolyl cis-trans isomerase A Alpha-1-antitrypsin Beta-2-glycoprotein 1
Trem-like transcript 1 protein isoform X1 Gelsolin von Willebrand factor
Tubulin beta-1 chain isoform X1 Coagulation factor V Complement C3
Pleckstrin Alpha-actinin-1 Serine protease inhibitor A3K
Phosphoglycerate kinase 1 Fibrinogen alpha chain Plasminogen
Nidogen-1 Latent-transforming GF beta-binding protein 1 Vitamin D-binding protein
Alpha-enolase Apolipoprotein A-I Beta-actin-like protein 2
Glia-derived nexin Apolipoprotein B-100 Myosin-9
Fermitin family homolog 3 Haptoglobin Platelet basic protein
Serotransferrin Amyloid beta A4 protein Fibrinogen beta chain
Actin, alpha cardiac muscle 1 Fibrinogen beta chain Carboxylesterase 1C
Plasminogen activator inhibitor 1 precursor Tropomyosin alpha-4 chain Filamin, alpha (Fragment)
Adenylyl cyclase-associated protein 1 isoform X2 Complement C4-A Alpha-enolase
Transgelin-2 Vinculin Fructose-bisphosphate aldolase A
Coagulation factor XIII A chain Platelet glycoprotein V Lysozyme C-2
Glyceraldehyde-3-phosphate dehydrogenase Fibrinogen gamma chain Murinoglobulin-1
https://doi.org/10.1371/journal.pone.0224891.t003
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unstimulated negative controls to account for the presence of platelet proteins likely derived
from in-vitro platelet manipulations and not representative of the activation response specifi-
cally induced by gamma-thrombin. Our study identified 1,918 total canine platelet proteins
and of those, characterized the thrombin-activated CAPS as a subset consisting of 693 pro-
teins. In comparison, three previous studies of thrombin receptor (PAR-receptor) activated
human platelets identified between 315–894 proteins in total [24, 25, 29]. These studies and
other qualitative descriptions of major human alpha-granule proteins included many CAPS
proteins such as platelet basic protein, thrombospondin, vWF, serglycin, vitronectin, fibrino-
gen, factor V, vitamin K-dependent protein S, plasminogen, platelet-derived growth factor and
plasminogen activator inhibitor 1. Similarly, both human and canine secretomes included
lysosomal proteins such as cathepsins and heparanase and major membrane proteins like
GPIIb-IIIa, GPIb-IX, GPVI, P-selectin, and CD9. As in a recent human report [37], the CAPS
proteins in soluble and pellet platelet fractions overlapped. This co-localization of soluble and
particulate proteins may represent binding or adsorption of soluble proteins to the particulate
fraction (e.g. fibrinogen, vWF, factor V, complement factors), or aggregates of soluble protein
complexes (e.g. thrombospondin-fibrinogen or immunoglobulins complexes). De Palio et al.
2018 demonstrated the complex composition of the extracellular vesiculosome, containing
multivesicular alpha-granules and cytoplasmic vacuoles containing organelles, e.g. mitochon-
dria [35].
In addition to many similarities between dogs and humans, we also found several interspe-
cies differences, including a subset of proteins that can be grouped into chemokines/cytokines,
immunoglobulins, growth factors and proteins involved in lipid metabolism (Table 2). We
moreover found some unexpected differences between CAPS proteins and the human platelet
secretome. The absence of platelet factor 4 in dogs is a novel finding. Platelet factor 4 and beta-
thromboglobulin are cleavage products of platelet basic protein found in high abundance in
human platelet secretomes. These products were absent from the CAPS and neither protein
has a canine entry in the Uniprot database. A basic local alignment (BLAST) of human platelet
factor 4 with canine proteins in the NCBI database identified 3 homologous proteins: platelet
basic protein precursor, chemokine C-X-C motif ligand 7, and interleukin-8 (IL-8). All of
these were defined as CAPS proteins suggesting that, in the dog, platelet basic protein is not
cleaved into platelet factor 4 or beta-thromboglobulin, but rather is cleaved into other chemo-
kines and cytokines of similar function, not found in the human secretome [29]. Our finding
of high canine platelet IL-8 content, compared to humans, supports a previous report of strong
correlation of IL-8 with platelet count in dogs [64].
Using mass spectrometry detection, we also identified three proteins that are uniquely pres-
ent in canine platelets: C-C motif chemokine 14, teneurin-3 and protein-arginine deiminase
type-3. Of these, C-C motif chemokine 14 was found to be a highly abundant CAPS protein.
After proteolytic activation, C-C motif chemokine 14 acts as a strong agonist on chemokine
receptors (CCR1 and CCR5), with downstream calcium mobilization, and resultant chemo-
taxis of monocytes, macrophages, T-lymphocytes and eosinophils [65]. The pro-fibrinolytic
proteases, urokinase-type and tissue-type plasminogen activators (uPA and tPA), are strong
activators of C-C motif chemokine 14 [65], and the active chemokine has also been found to
mediate anti-viral effects through CCR5 internalization, a major entry protein for human
immunodeficiency virus [66]. In humans, this chemokine is a high concentration plasma pro-
tein [67], and potential contamination of the canine platelet secretome with plasma-derived
proteins cannot be ruled out. However, it is less probable for proteins with high activated/con-
trol MS1 ratios like C-C motif chemokine 14.
Species-differences were also apparent in the relative abundance of releasate proteins. PN-1
was a highly abundant CAPS protein with low or undetectable abundance in the human and
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murine secretomes, respectively. PN-1, also known as SERPINE2 and glia derived nexin, has
been identified as an alpha-granule protein [68] with very low plasma concentration [69]. As a
potent thrombin inhibitor, has strong antithrombotic properties [68], as well as anti-fibrino-
lytic effects, through inhibition of uPA, tPA and plasmin [70]. Fibronectin, metalloproteinase
inhibitor-1 and Trem-like 1 also had significantly lower estimated abundances in human and
murine releasates vs. CAPS. In contrast, the CAPS proteins were relatively deficient in other
proteins. For example, vWF ranked 16 and 28 in abundance for murine [47] and human [29]
platelets, respectively, but in the canine platelet secretome, it ranked 288. Together, these fea-
tures of CAPS render the dog a potential model for defining the actions of proteins unique to
CAPS such as C-C motif chemokine 14 and PN-1, or for studying proteins relatively deficient
in canine platelet, e.g. the contribution of platelet vs. non-platelet vWF pool.
Our study examined the response to thrombin, a physiologic platelet agonist, and identi-
fied CAPS proteins based on comparisons with paired unstimulated control samples. While
this allowed us to account for potential non-specific in-vitro platelet activation, and more
accurately define CAPS in the controlled agonist-induced releasate, it complicates direct
comparisons with previous studies. Secretomes reported by others do not include negative
(unstimulated) controls, and could include a contaminating cohort of non-secreted platelet
proteins. The negative control samples of the present study were processed identically to the
activated samples, with substitution of an equivalent volume of saline for thrombin. No sub-
sequent steps were included to prevent potential platelet activation during releasate collec-
tion in either saline controls or thrombin-stimulated samples. While unlikely to have
influenced core protein profiles for moderate or low abundance proteins; the observed con-
trol/stimulated ratio differences for high abundance core proteins may have been somewhat
reduced. Additional method-related differences from previous human reports include the
use of human gamma-thrombin. This hydrolyzed form of gamma-thrombin selectively acti-
vates platelet protease-activated receptor (PAR) 4 [71], and importantly lacks the ability to
interact with fibrinogen to form a fibrin clot [72]. This is a major advantage for isolation of
secreted proteins, as the presence of an unwanted fibrin clot may influence the proteomic
signature for the secreted proteins, through removal of proteins adsorbed to fibrin, platelet
aggregates and cell debris. This advantage was also reflected in the canine dataset by signifi-
cantly lower abundance for cytoskeletal-associated proteins, e.g. talin-1. The overall CAPs
protein profile may also have been influenced by method of protein extraction, solubiliza-
tion and purification, and their possible association with platelet aggregates and debris,
removed during sample fractionation. The generation of tryptic peptides in-gel vs in-solu-
tion can moreover influence the proteins detected, including basic and hydrophobic pro-
teins, with higher recovery of less abundant proteins favored by use of in-gel digestion [73].
The differing experimental conditions between the present study and those of the human
and murine secretomes limit the comparison of the secretome protein profiles. Methods used
for proteomics continue to evolve with advances in technology and are a potential source of
variation between protein profiles for canine, human and murine secretomes. Another poten-
tial limitation of our study was that platelet suspensions used for activation were not adjusted
to a standard platelet concentration, and the variable platelet recoveries could reflect differ-
ences in baseline platelet numbers, platelet loss during washing, or platelet activation. We
compensated for this through standardized sample loading during MS analysis. The very high
number of proteins identified in our study compared to previous reports indicates that our
protocol was capable of detecting even trace secretome proteins. Differences in the number of
proteins identified between dogs may also reflect potential analytical variation for the
nanoLC-MS/MS, which may account for the significantly lower total number of proteins iden-
tified in dog 1. For this reason, we established presence in 2/3 (not 3/3) dogs as a criterion for
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identification of CAPS proteins. As for many human studies, this small number of dogs repre-
sents a starting point for the method development and preliminary characterization of CAPS.
The extent of inter-individual biological variation in the platelet releasate among dogs remains
to be established using a larger sample size, as recently described for humans [29].
Conclusions
We have described a detailed and highly sensitive protocol for identification of proteins
secreted from thrombin-activated canine platelets. Using this method, we have taken the first
step in defining a reference database for healthy CAPS proteins. Similarities between CAPS
and the human secretome confirm the utility of dogs as translational models of human disease.
But our dataset also allowed identification of important species differences and findings poten-
tially unique to dogs. Among these differences were replacement of platelet factor 4 with alter-
native cleavage products of platelet basic protein, novel and/or highly secreted platelet proteins
like C-C motif chemokine 14 and PN-1, and markedly lower abundance of functionally signifi-
cant human alpha-granule proteins, like vWF. These results provide a platform for further
investigations into disease-related CAPS profiles and for future comparative proteomic studies
to unravel the role of platelet activation in acquired disease shared by dogs and humans, e.g.
cancer.
Supporting information
S1 Fig. Flow cytometric gating strategy. Gating strategy for the flow cytometric analysis of
platelet CD62P expression. Platelets were sequentially identified by means of forward scatter,
side scatter and CD9 expression (top and middle panels). To assess post-wash platelet activa-
tion and platelet responsiveness, CD62P (P-selectin) expression of the CD9-positive platelet
population (bottom panel), was analyzed relative to isotype control (red population), in the
post-wash platelet samples before (light blue population) and after (green population) gamma-
thrombin stimulation. FSC: forward scatter, SSC: side scatter.
(TIF)
S2 Fig. Flow cytometric gating strategy. Gating strategy for leukocyte identification by
means of CD18 expression. Gates for granulocytes and monocytes/lymphocytes were identi-
fied using lysed canine whole blood (top panel). CD18 expression relative to isotype control
(red population), were documented for granulocytes (middle panel, light blue population) and
for monocytes/lymphocytes (bottom panel, blue population). The template was subsequently
applied in the assessment of leukocyte contamination of the washed platelets samples. FSC:
forward scatter, SSC: side scatter.
(TIF)
S3 Fig. Light transmittance aggregometry. Representative aggregation traces for washed
platelets following addition of 50 nM gamma-thrombin (trace 1–4) or 0.15 M NaCl2 vehicle
control (trace 5–8). Increasing light-transmission shown by arrow.
(TIF)
S1 Table. Mother table for all proteins identified. The listed 1,918 proteins are sorted A-Z. 1
peptide ID (marked in red): n = 573 (29.9%). ’ID only’ designates proteins present in trace
amounts, a blank space means the protein was not detected.
(XLSX)
S2 Table. Canine proteins also reported in the global platelet proteome. The 1,593 proteins
found in both the dogs and in the Burkhart et al. 2012 global platelet proteome. The proteins
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are listed A-Z. Splice variants are in italic and 1 peptide identifications (n = 392, 24.6%) are
marked in red.
(XLSX)
S3 Table. CAPS proteins. The 693 proteins found in at least 2/3 dogs with a stim/control
ratio� 2. The table is divided into proteins found in both the soluble and the pellet fraction
(n = 144), proteins solely found in the soluble fraction (n = 360), and proteins solely found in
the pellet fraction (n = 189). They are further sorted based on highest to lowest MS1-abun-
dance. Fifty proteins (7.2%) total were identified with a single peptide.
(XLSX)
S4 Table. Significantly enriched GO-annotations for ‘cellular compartment’. GO-annota-
tions that were significantly enriched for the 693 CAPS proteins found in at least 2/3 dogs with
a stim/control ratio� 2.
(XLSX)
S5 Table. Significantly enriched GO-annotations for ‘molecular function’. GO-annotations
that were significantly enriched for the 693 CAPS proteins found in at least 2/3 dogs with a
stim/control ratio� 2.
(XLSX)
S6 Table. Inter-species platelet secretome comparisons. The top 100 most abundantly
secreted platelet proteins in dogs are compared with those of humans [29] and mice [47].
Noteworthy differences are highlighted in bold.
(XLSX)
S7 Table. Protein raw data files. All protein raw data files generated from Dog 1 (D1).
(XLSX)
S8 Table. Protein raw data files. All protein raw data files generated from Dog 2 (D2).
(XLSX)
S9 Table. Protein raw data files. All protein raw data files generated from Dog 3 (D3).
(XLSX)
S10 Table. Protein raw data files. All protein raw data files generated for pooled flow-through
samples from Dog 1–3.
(XLSX)
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